Becton Dickinson (BDX) Research & Development (2009 - 2026)
Becton Dickinson's (BDX) quarterly Research & Development came in at $258.0 million in Q2 2026, up 12.17% year-over-year from $230.0 million in Q2 2025, and up 3.61% quarter-over-quarter from $249.0 million in Q1 2026.
Analysis
Becton Dickinson (BDX) Research & Development (2009 - 2026) Analysis & Trends
Becton Dickinson (BDX) has reported Research & Development for 18 consecutive years, with $258.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Research & Development rose 12.17% year-over-year to $258.0 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 23.94% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 6.3% from the prior year.
- Research & Development was $258.0 million for Q2 2026 at Becton Dickinson, up from $249.0 million in the prior quarter.
- Over five years, Research & Development peaked at $559.0 million in Q3 2025 and troughed at $230.0 million in Q2 2025.
- A 5-year average of $308.1 million and a median of $301.0 million in 2022 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 85.1% in 2025, down 23.08% in 2025.
- Over 5 years, Research & Development stood at $313.0 million in 2022, then decreased by 7.35% to $290.0 million in 2023, then increased by 18.28% to $343.0 million in 2024, then dropped by 10.79% to $306.0 million in 2025, then declined by 15.69% to $258.0 million in 2026.
- The last three Research & Development figures came in at $258.0 million (Q2 2026), $249.0 million (Q1 2026), and $306.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Becton Dickinson | 48.41 Bn | 47.55 Bn | 2.32 Bn | 258.00 Mn |
| 2 | Medline | 27.78 Bn | 25.10 Bn | 2.22 Bn | - |
| 3 | West Pharmaceutical Services | 24.42 Bn | 23.98 Bn | 329.20 Mn | 19.70 Mn |
| 4 | Baxter International | 12.49 Bn | 10.34 Bn | 1.03 Bn | 129.00 Mn |
| 5 | Stevanato Group S.p.A | 5.70 Bn | 5.59 Bn | 100.91 Mn | 7.22 Mn |
| 6 | Acme United | 235.29 Mn | 230.25 Mn | 26.69 Mn | - |
| 7 | Rockwell Medical | 31.39 Mn | 6.60 Mn | 3.24 Mn | 577,000.00 |
| 8 | Retractable Technologies | 21.15 Mn | -18.72 Mn | 190,852.00 | 1.53 Mn |
| 9 | United Health Products | 8.85 Mn | 8.82 Mn | - | 3,852.00 |
| 10 | Cuprina Holdings (Cayman) | 7.88 Mn | 4.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 258.00 Mn |
| Mar 31, 2026 | 249.00 Mn |
| Dec 31, 2025 | 306.00 Mn |
| Sep 30, 2025 | 559.00 Mn |
| Jun 30, 2025 | 230.00 Mn |
| Mar 31, 2025 | 232.00 Mn |
| Dec 31, 2024 | 343.00 Mn |
| Sep 30, 2024 | 302.00 Mn |
| Jun 30, 2024 | 299.00 Mn |
| Mar 31, 2024 | 299.00 Mn |
| Dec 31, 2023 | 290.00 Mn |
| Sep 30, 2023 | 281.00 Mn |
| Jun 30, 2023 | 306.00 Mn |
| Mar 31, 2023 | 337.00 Mn |
| Dec 31, 2022 | 313.00 Mn |
| Sep 30, 2022 | 300.00 Mn |
| Jun 30, 2022 | 315.00 Mn |
| Mar 31, 2022 | 327.00 Mn |
| Dec 31, 2021 | 314.00 Mn |
| Sep 30, 2021 | 368.00 Mn |